Therapeutic resistance to the novel JAK2 inhibitor CHZ868 in MPN is dependent on MEK-ERK activation and is targetable Meeting Abstract
| Authors: | Szybinski, J.; Codilupi, T.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C. |
| Abstract Title: | Therapeutic resistance to the novel JAK2 inhibitor CHZ868 in MPN is dependent on MEK-ERK activation and is targetable |
| Meeting Title: | 2020 Swiss Oncology and Hematology Congress (SOHC) |
| Journal Title: | Swiss Medical Weekly |
| Volume: | 150 |
| Issue: | Suppl. 247 |
| Meeting Dates: | 2020 Nov 18-21 |
| Meeting Location: | Virtual |
| ISSN: | 1424-7860 |
| Publisher: | E M H Swiss Medical Publishers Ltd |
| Date Published: | 2020-11-17 |
| Start Page: | 10 S |
| Language: | English |
| ACCESSION: | WOS:000592781900019 |
| PROVIDER: | wos |
| PUBMED: | 33200807 |
| DOI: | 10.4414/smw.2020.20411 |
| Notes: | Meeting Abstract: O18 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
